Pelacarsen sodium

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePelacarsen sodium
Drug Alias NameAKCEA-APO(a)-LRxIONIS-APO(a)-LRxISIS-APOALRxIONIS-APO-LRxISIS-APO(a)-LRx +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionApolipoprotein(a) inhibitors
TargetsApolipoprotein(a)
Therapy Area/IndicationsHyperlipoproteinemiasAtherosclerosisAortic Valve Stenosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgNovartis Pharma Stein AgChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesIonis Pharmaceuticals IncAkcea Therapeutics Inc
Active IndicationsHyperlipoproteinemiasAtherosclerosisAortic Valve Stenosis +[5] 
Inactive IndicationsRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A